Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Colorectal Neoplasms 208Pancreatic Neoplasms 130Stomach Neoplasms 80Carcinoma, Hepatocellular 77Esophageal Neoplasms 58Carcinoma, Non-Small-Cell Lung 58Colonic Neoplasms 52Rectal Neoplasms 48Breast Neoplasms 48Ovarian Neoplasms 42Cholangiocarcinoma 39Neoplasm Metastasis 37Neoplasms 36Lung Neoplasms 35Liver Neoplasms 31Gastrointestinal Neoplasms 30Prostatic Neoplasms 29Melanoma 29Sarcoma 26Endometrial Neoplasms 25Carcinoma, Renal Cell 24Squamous Cell Carcinoma of Head and Neck 22Biliary Tract Neoplasms 22Urinary Bladder Neoplasms 20Esophageal Squamous Cell Carcinoma 19Uterine Cervical Neoplasms 16Head and Neck Neoplasms 15Gastrointestinal Stromal Tumors 15Adenocarcinoma Of Esophagus 15Small Cell Lung Carcinoma 14

Interventions

Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Gastroenteropancreatic Neuroendocrine Tumor × Gastrointestinal × 30 days × Clear all
NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
220 enrolled
EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡